Efficacy and safety of convalescent plasma versus standard care in hospitalized 1 2 patients with COVID-19 from the Peruvian Social Security Health System: open-3 label, randomized, controlled clinical trial 4 Cristian Villanueva¹, Ibeth Neyra¹, Arturo Sagastegui ¹, Ausberto Chunga¹, Martin 5 Ovanguren¹, Martina Guillermo-Roman², Sulv Soto-Ordoñez², Jorge L. Maguiña², 6 Yamilee Hurtado-Roca², Percy Soto-Becerra², Roger V. Araujo-Castillo² 7 8 ¹Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú. 9 ²Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud, Lima, 10 Perú 11 12 * Corresponding: 13 Roger V. Araujo-Castillo, MD Address: Cápac Yupanqui 1400 - Jesus María, Lima 11, Perú 14 Phone: (511) 748 1111 ext 2143 15 E-mail: araujocaroger@gmail.com 16 17 18 **Financing** This clinical trial has been co-financed by two institutions of the Government of Peru, the 19 Institute for the Evaluation of Technologies in Health and Research - IETSI of the Social 20 21 Security of Health (EsSalud) and the National Council of Science, Technology and Technological Innovation (CONCYTEC) through peer-reviewed external financing: the 22 National Fund for Scientific Research, Technological Development and Technological 23

Innovation (FONDECYT), subsidy (N° 068-2020-FONDECYT). This grant was awarded

- to CV, IN, AS, AC, MO, JLM, YH, PSB and RA. The funders had no role in study design, 25
- 26 data collection and analysis, decision to publish, or manuscript preparation.

Conflicts of interest 28

27

30

31

36

40

The authors declare not to have any interest conflicts. 29

Data availability

- The raw data was generated at the Institute for the Evaluation of Technologies in Health 32
- and Research IETSI of Peru's Social Security of Health (EsSalud). Restrictions apply to 33
- 34 the public availability of these data due to institutional patient data sharing policies.
- However, the data is available upon reasonable request from the author. 35
- 37 Clinical Trial Registration Number: This clinical trial has been registered in the
- Peruvian Registry of Clinical Trials (REPEC, by Spanish acronym) with the following 38
- 39 ID: PER-013-20.

ABSTRACT

41

64

42 **OBJECTIVES:** To assess the efficacy and safety of convalescent plasma plus standard of care (CP + SoC) compared with standard of care (SoC) alone in patients hospitalized 43 for moderate to severe COVID-19 who do not yet require mechanical ventilation. 44 **METHODS:** Phase 2 randomized, parallel-group, randomized, open-label, controlled, 45 superiority, single-center clinical trial. This clinical trial has been registered in REPEC 46 with the following ID: 013-20. Hospitalized adult patients with moderate to severe 47 COVID-19 were enrolled. The allocation ratio was 1:1 in a variable-size permuted block 48 randomization scheme. The primary outcome was death 28 days after the intervention. 49 50 Secondary outcomes were mortality at 14 and 56 days, time to death at 56 days, time in the ICU at 28 days, time on a mechanical ventilator at 28 days, frequency of adverse 51 events, and frequency of serious adverse events. 52 53 **RESULTS:** A total of 64 participants were enrolled, 32 were assigned to CP + SoC, and 32 to SoC. One participant assigned to CP + SoC withdrew his informed consent before 54 applying the treatment. At day 28, there were no statistically significant differences for 55 the primary outcome between the CP + SoC and SoC groups (relative risk: 2.06; 95%CI 56 0.73 to 7.11; p = 0.190). No differences were found in the incidences of mortality at 56 57 58 days (hazard ratio: 2.21; 95%CI 0.66 to 7.33; p = 0.182), admission to the ICU at 28 days (sub-hazard ratio: 2.06; 95%CI 0.57 to 8.55; p = 0.250), admission to mechanical 59 ventilation at 28 days (sub-hazard ratio: 2.19; 95%CI 0.57 to 8.51; p = 0.260). Estimates 60 for days 14 were similar. No infusion-related adverse events were reported during the 61 study. There were no statistically significant differences in the frequency of any adverse 62 events (odds ratio: 2.74; 95%CI 0.90 to 9.10; p = 0.085) or the frequency of serious 63

adverse events (odds ratio: 3.60; 95%CI 0.75 to 26.1; p = 0.75).

CONCLUSIONS: No evidence was found that CP had a significant effect in reducing 65 66 28-day mortality. There was also no evidence that the frequency of adverse events was higher in those who received CP + SoC than those who received only SoC. 67 68 Key Words: Convalescent plasma, COVID-19, SARS-CoV-2, clinical trial. 69 70

Introduction 72 73 The SARS-CoV-2 virus causes coronavirus disease 2019 (COVID-19), identified in Wuhan, China, in December 2019 and declared a pandemic on March 12, 2020, a few 74 months after the first case was reported (1-3). In the absence of available treatments, 75 clinical trials initially focused on evaluating the replacement of interventions with 76 recognized efficacy for other infectious diseases, such as antiparasitic, antiviral, anti-77 inflammatory drugs, anticoagulants, and convalescent plasma, among others (4). 78 79 For more than a century, convalescent plasma (CP) has been used in the treatment of 80 81 various diseases of viral origin: severe acute respiratory syndrome (SARS), Eastern respiratory syndrome (MERS), avian influenza A (H5N1), Spanish flu A H1N1 82 pandemic, among others (5,6). Theoretically, antibodies in the plasma of recovered 83 84 COVID-19 individuals would be passive immunization agents for the immune system of patients with active disease (7); however, empirical evidence about its efficacy on 85 important outcomes was anecdotal, coming mainly from case series or observational 86 studies (5). 87 88 Initially, the studies showed conflicting evidence, and even the available systematic 89 reviews and meta-analyses did not find consistent results (8-12). Some systematic 90 reviews and meta-analyses concluded that PC shows a potential reduction in mortality, 91 although with statistically uncertain estimates (8–10). However, other systematic reviews 92 and meta-analyses concluded that PC does not offer any benefit to adverse outcomes of 93 COVID-19 (11.12), but the quality of the evidence reviewed was low. These inconsistent 94 results showed the need for more controlled clinical trials to clarify the uncertainty about 95

the efficacy of PC in the treatment of COVID-19.

perpetuity.

It is made available under a CC-BY 4.0 International license .

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

This clinical trial was conducted in this context of uncertainty about the efficacy of PC. However, as scientific evidence accumulated, it became increasingly clear that PC was ineffective in treating patients hospitalized for COVID-19 (13). For this reason, this study was terminated early. Although the current consensus indicates that there is high certainty that treatment with PC is not effective in reducing outcomes of death, admission to the ICU, or mechanical ventilation (13–15), there are still some controversies about whether these studies evaluated the doses, appropriate application times (16–21) and uncertainties about their safety (13). As of May 20, 2021, 100 clinical trials on CP had been registered, but only under 33% had been published (13), so the publication of the findings will contribute to resolving the uncertainties associated with CP therapy. This study reports the results of a clinical trial that aimed to evaluate the efficacy and safety of PC plus standard of care (SoC) compared to SoC alone in outcomes of patients hospitalized for COVID-19. The main hypothesis of this clinical trial was that convalescent plasma treatment in patients with moderate to severe COVID-19, who do not yet require a mechanical ventilator, is effective in reducing 28-day mortality. Efficacy against intensive care unit (ICU) admission, ventilator, and adverse events were also evaluated. The article was written following the CONSORT 2010 guidelines (Consolidated Standards of Reporting Trials) (22). Methods Study design Phase 2, randomized, controlled, open-label, parallel-group, superiority, single-center clinical trial. The study was approved by the Transitory National Research Ethics

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

b. D-dimer > 1 mg/L

Committee (CNTEI) -COVID-19 through Certificate of Approval - CNTEI-007-2020 dated June 19, 2020. The study is registered in the Peruvian Registry of Clinical Trials (REPEC) with code PER-013-20 (23) and was approved by the National Institute of Health through Directorial Resolution 198-2020-OGITT-INS dated June 25, 2020. The last version of the approved protocol, translated to English for publication purposes, is available in S1 File. Ethical approval and informed consent form are in the S2 and S3 Files. A detailed description of procedures is available in the Manual of Procedures whose last version is in the S4 File. This study followed the CONSORT recommendations for reporting clinical trials (S5 File). Study population This trial was conducted in the Emergency Service and the Transfusion Medicine Service of the Edgardo Rebagliati Martins National Hospital (HNERM), a tertiary care hospital located in Lima, the capital of Peru. Between September 2020 and April 2021, patients who met the following inclusion criteria were enrolled: 1. Adult male or female patient ≥18 years of age requiring hospitalization or hospitalized for COVID-19 without the need for mechanical ventilation (invasive or non-invasive) at the time of enrollment. 2. Written informed consent before performing study procedures. 3. Laboratory-confirmed diagnosis of SARS-CoV-2 infection by RT-PCR in nasopharyngeal or oropharyngeal swabs. 4. Patients at risk of progression of COVID-19 defined as the presence of two or more of the following laboratory values: a. Ferritin > 500 ng/mL

perpetuity.

It is made available under a CC-BY 4.0 International license.

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

c. C-reactive protein > 15 mg/L d. Total lymphocytes <1000/mm3 or neutrophil/lymphocyte ratio >3.13 5. Or patients with a clinical manifestation of pulmonary compromise defined by the presence of two or more of the following clinical parameters a. Dyspnoea b. Respiratory rate greater than or equal to 30 per minute c. Oxygen saturation less than 93% d. PaO2/FiO2 less than 300 and pulmonary infiltrate greater than 50% in the 24 to 48 hours after the initial evaluation Likewise, patients who met any of the following criteria were excluded: 1. Transfusion of any blood product within 120 days before administration of convalescent plasma. 2. Active pregnancy detected by a qualitative test that detects the hormone human chorionic gonadotropin (hCG) in the urine. 3. Current participation in a randomized clinical trial or past involvement in a clinical trial, and less than 30 days have passed since your last study visit. 4. Patient has life-threatening COVID-19 illness defined as one or more of the following: a. Respiratory failure, ventilatory type, defined as the need for invasive mechanical ventilation (with endotracheal intubation) or ECMO (extracorporeal oxygenation). b. Septic shock, defined as having criteria for sepsis (an increase of two or more points on the Sequential Organ Failure Assessment (SOFA) scale) (17) and requiring vasopressors to maintain MAP ≥ 65 mmHg after adequate hydration.

c. Multiple organ dysfunction or failure, defined as the dysfunction of two or more systems other than the respiratory system. System dysfunction will be considered when a score of 2 or more is obtained on the SOFA scale in the following systems: coagulation, liver, cardiovascular, central nervous system, or kidney. The SOFA criteria used in this clinical trial are in the S1 Table.

Study intervention

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

All participants received SoC for COVID-19. In addition, the treatment arm received ABO blood group system-compatible convalescent plasma from recovered COVID-19 patients (called donors) as an add-on therapy to the SoC. Other compatibilities, such as the Rh factor, were unnecessary for the plasma transfusion since it is free of red blood cells. Once a patient was assigned to the CP treatment arm, the CP bag was thawed, stored at 2-6°C, and used within 24 hours. A complete unit of plasma was administered intravenously as one dose, with a volume between 200-400 mL of convalescent plasma contained in a transfusion bag, at a recommended flow rate of 150-200 mL/h or less depending on patient tolerance. The plasma transfusion was in charge of one health personnel from the Transfusion Medicine Service who fulfilled the role of transfuser and was not part of the research team. The control arm received only SoC for COVID-19.

Outcomes

- The study's primary outcome was the cumulative incidence of mortality (all causes) through day 28 after CP administration. Secondary outcomes were:
 - Cumulative incidence of ICU admission at 14 and 28 days.
 - Cumulative incidence of mechanical ventilation or extracorporeal oxygenation (ECMO) on day 14 and day 28 after randomization.

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

• Cumulative incidence of mortality (all causes) on days 14 and 56 after CP administration. • Safety evaluations of CP + SoC compared to SoC alone up to day 28 considering the cumulative incidence of serious adverse events (SAEs) and infusion-related adverse reactions. Sample size For an open-label, parallel-group, standard-of-care, controlled, randomized (1:1 ratio) superiority clinical trial and cumulative incidence of all-cause mortality at day 28 as the primary outcome, a sample size of 190 patients (95 per arm) assuming 21% mortality in the SoC arm (18) and an absolute difference of ~14% (relative risk of 0.33 or ~7% mortality in the CP arm), with a power statistic of 80% and a two-sided alpha level of 5% for a chi-square test of homogeneity without continuity correction. In addition, he estimated that approximately 63 PC donors would be needed. **Procedures** The patients with COVID-19 were recruited at the HNERM Emergency Department through daily screening of medical records or on-site identification of the patients. Donors were invited through local print and audiovisual media advertising, which the Ethics Committee previously approved. Potentially eligible candidates were invited for a complete evaluation at the Blood Bank of the HNERM Transfusion Medicine Service. The investigators of this study, certified and trained in Good Clinical Practices and Ethics in Research in Humans, conducted the process of obtaining the subject's informed consent in accordance with Peruvian regulations and internationally accepted standards. The patients received a presentation with key aspects of the clinical trial, they read the written informed consent document together with the investigator and their doubts were

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

answered by him. In the end, the researcher confirmed that the information provided in the consent has been understood. When there were no more questions and the patient expressed understanding of the informed consent document, they were asked if she wishes to participate in the study. If accepted, the informed consent form was signed in duplicate by the patient or her legal representative, in case the patient is incapacitated, and by one of the researchers. In case she did not want to sign but did consent, her fingerprint was placed. Finally, one original informed consent form was delivered to the patient, and the other original was filed in a safe place. When the condition and severity of the patients who cannot consent did not allow the taking of informed consent in writing, consent was taken orally, recording the process in audiovisual media or digital images; and then, when feasible, obtaining the signature of the research subject in the written informed consent format. Due to the impediment to receiving medical visits that the COVID-19 services have imposed on the relatives of hospitalized patients, it was possible to contact legal representatives or relatives by phone or instant messaging to request their support or consent if the participant is prevented from doing so. Donors also received information about the clinical trial and gave their written informed consent before donating convalescent plasma. Patients and donors were informed about the possibility of collecting and storing an additional serum and plasma sample for up to one year for future use in research related to SARS-CoV-2. If they accepted, the participant or her legal representative signed written informed consent for future use of the biological sample. Participants were randomly assigned to SoC alone (control arm) or treatment group (CP + SoC) with a 1:1 allocation according to a computer random number generator program that used permuted blocks of random size to ensure the balance of arms and the unpredictability of treatment assignments at any time during the trial. The random sequence was generated using the ado ralloc package (19) in Stata/SE version 16.1 for Microsoft Windows Pro 10 (StataCorp. 2019. College Station, TX: StataCorp LLC.). To ensure concealment, block sizes were not disclosed until endpoint analysis and a central randomization scheme were implemented. The random assignment list was generated by a randomization officer and was kept hidden without sharing with any research team member until the clinical trial was completed. The randomization officer was a member of the team who was not part of the staff of evaluators or therapists, so integrity was guaranteed during the randomization process. A detailed timeline is provided in S1 Fig.

Statistical analysis

The primary outcome was the cumulative incidence of death at 28 days after randomization. This analysis was by intention to treat. The effect of CP + SoC versus SoC alone on the cumulative incidence of mortality at 28 days was estimated using an adjusted relative risk (aRR) obtained from a log-binomial regression model that included the treatment variable and the block variable. Estimating the effect on mortality at 14 days followed the same approach described. However, the effect on 56-day mortality was assessed using a Cox regression that included treatment and block factor as covariates. The effect of CP + SoC versus SoC alone on these outcomes was estimated using adjusted hazard rate (HR) ratios. Survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. The effect of CP + SoC on admission to the ICU (at 14 and 28 days) and admission to mechanical ventilation (at 14 and 28 days), compared to SoC alone, was estimated using the sub-hazard ratio (subHR) considering death as a competitive event and obtained from a Fine and Gray model. Cumulative incidence functions were estimated and compared using Gray test. All analyzes were

estimated with a 95% confidence interval and a significance level of 5%. Statistical analyzes were performed with R version 4.1.3 software.

Results

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Patients

Between September 2020 and April 2021, 64 research subjects who met the selection criteria were enrolled, randomly assigning 32 to each study arm; One participant randomized to the intervention arm withdrew from the study before the application of PC, so 31 patients were assigned to convalescent plasma plus standard treatment and 32 to standard treatment alone (Fig 1).

Fig 1. Enrollment and random assignment

The mean age of the patient population was 59.5 years (IQR: 46 to 72); 20.0% were women, and 20% had at least one comorbidity at study entry. The median time from onset of COVID-19 symptoms to enrollment was 13 days. The distribution of sociodemographic and clinical characteristics is shown in Table 1.

Table 1. Characteristics of the participants at enrollment

| Characteristics | CP + SoC (n = 32) | Only SoC (n = 32) |
|-------------------------|--------------------|-------------------|
| Sex | | |
| Male | 23 (71.9%) | 28 (87.5%) |
| Female | 9 (28.1%) | 4 (12.5%) |
| Age, years | 62.5 (51.8, 72.0) | 56.5 (46.0, 69.0) |
| Arterial hypertension | 6 (18.8%) | 6 (18.8%) |
| Mellitus diabetes | 4 (12.5%) | 6 (18.8%) |
| Pulmonary fibrosis | 0 (0.0%) | 1 (3.1%) |
| Asthma | 0 (0.0%) | 1 (3.1%) |
| Heart disease | 1 (3.1%) | 1 (3.1%) |
| Cerebrovascular disease | 0 (0.0%) | 1 (3.1%) |
| | | |

| Obesity | 9 (28.1%) | 7 (21.9%) |
|---------------------------------------|--------------------------------|-------------------------------|
| Cancer | 1 (3.1%) | 1 (3.1%) |
| Hypothyroidism | 0 (0.0%) | 2 (6.2%) |
| Hemoglobin, g/dL | 14.0 (13.2, 15.3) | 14.4 (13.2, 15.3) |
| Hemoglobin categories | 1 (10.2, 10.0) | 1 (10.2, 10.0) |
| <14 g/dL | 14 (45.2%) | 14 (43.8%) |
| 14-18 g/dL | 17 (54.8%) | 17 (53.1%) |
| >=18 g/dL | 0 (0.0%) | 1 (3.1%) |
| Lymphocyte count, 1/uL | 760.0 (625.0, 1,060.0) | 890.0 (737.5, |
| Hemoglobin categories | 700.0 (023.0, 1,000.0) | 1,542.5) |
| <900/uL | 19 (61.3%) | 16 (50.0%) |
| 900-5200/uL | 12 (38.7%) | 16 (50.0%) |
| Neutrophil count, 1/uL | 9,360.0 (6,670.0, 12,845.0) | 7,520.0 (4,495.0, 9,385.0) |
| Neutrophil Count Categories | , , | , , |
| 1800-8000/uL | 12 (38.7%) | 17 (53.1%) |
| >8000/uL | 19 (61.3%) | 15 (46.9%) |
| Platelet count, 1000/uL | 318.0 (214.0, 420.5) | 262.5 (179.5, 380.0) |
| Platelet Count Categories | | |
| <130 x 1000/uL | 2 (6.5%) | 2 (6.2%) |
| 130-400 x 1000/uL | 19 (61.3%) | 23 (71.9%) |
| >400 x 1000/uL | 10 (32.3%) | 7 (21.9%) |
| Prothrombin time, sec | 11.1 (10.6, 11.9) | 11.0 (10.6, 11.9) |
| PT Categories | | |
| <10.5 seg | 6 (20.0%) | 5 (15.6%) |
| 10.5-13.0 seg | 22 (73.3%) | 25 (78.1%) |
| >13.0 seg | 2 (6.7%) | 2 (6.2%) |
| Partial thromboplastin time, sec | 36.1 (32.2, 39.6) | 34.0 (31.7, 36.4) |
| TPT Categories | | |
| 24.0-37.0 seg | 0 (0.0%) | 0 (0.0%) |
| >37.0 seg | 12 (100.0%) | 7 (100.0%) |
| Serum glucose, mg/dL | 136.0 (118.0, 183.0) | 137.0 (99.8, 185.5) |
| Serum glucose categories | | |
| 74-106 mg/dL | 3 (9.7%) | 10 (31.2%) |
| >106 mg/dL | 28 (90.3%) | 22 (68.8%) |
| Serum creatinine, mg/dL | 0.7 (0.6, 0.8) | 0.8 (0.7, 0.9) |
| Glutamic-oxalacetic transaminase, U/L | 50.0 (39.0, 82.5) | 58.5 (41.0, 67.5) |
| TGO Categories | | |
| 0.0-34.9 U/L | 0 (0.0%) | 0 (0.0%) |
| >34.0 U/L | 25 (100.0%) | 25 (100.0%) |
| Glutamic-pyruvic transaminase, U/L | 75.0 (48.0, 119.5) | 69.5 (51.2, 116.5) |
| TGP Categories | | |
| 0.0-49.0 U/L | 8 (25.8%) | 8 (25.0%) |
| >49.0 U/L | 23 (74.2%) | 24 (75.0%) |
| Serum sodium, mmol/L | 139.2 (136.8, 142.1) | 139.2 (136.8, 140.8) |
| Serum sodium categories | | |

| <132.0 mmol/L | 1 (3.2%) | 0 (0.0%) |
|---|------------------------|---------------------------|
| 132.0-146.0 mmol/L | 30 (96.8%) | 32 (100.0%) |
| Serum potassium, mmol/L | 4.1 (3.9, 4.4) | 4.2 (4.0, 4.4) |
| Serum potassium categories | | |
| <3.5 mmol/L | 1 (3.3%) | 1 (3.1%) |
| 3.5-5.5 mmol/L | 29 (96.7%) | 31 (96.9%) |
| C-Reactive Protein, mg/dL | 9.2 (5.1, 15.4) | 6.1 (3.2, 11.2) |
| PCR Categories | | |
| 0.0-100.0 mg/dL | 31 (100.0%) | 31 (100.0%) |
| Ferritin, ng/mL | 822.0 (666.9, 1,446.0) | 869.9 (575.6, 1,362.5) |
| Ferritin Categories | | |
| 28.0-365.0 ng/dL | 3 (9.7%) | 4 (12.5%) |
| >365.0 ng/dL | 28 (90.3%) | 28 (87.5%) |
| D-dimer, mg/mL | 0.7 (0.4, 1.1) | 0.6 (0.5, 0.9) |
| D-Dimer Category | | |
| 0.00-0.54 ug/mL | 11 (39.3%) | 12 (40.0%) |
| >0.54 ug/mL | 17 (60.7%) | 18 (60.0%) |
| Lactic dehydrogenase, U/L | 390.0 (289.5, 479.0) | 347.5 (245.0, 403.8) |
| DHL Categories | | |
| 120.0-246.0 U/L | 5 (16.1%) | 9 (28.1%) |
| >246.0 U/L | 26 (83.9%) | 23 (71.9%) |
| Quantification of anti-SARS-CoV-2 antibodies - IgG, AU/mL | 39.5 (15.9, 69.1) | 37.8 (16.7, 67.5) |
| Categories of Ab anti-SARS-CoV-2 IgG | | |
| Non-reactive | 4 (12.9%) | 7 (21.9%) |
| Reactive | 27 (87.1%) | 25 (78.1%) |
| Quantification of anti-SARS-CoV-2 antibodies - IgM, AU/mL | 10.7 (2.3, 59.7) | 5.4 (2.0, 23.8) |
| Categories of Ab anti-SARS-CoV-2 IgM Non-reactive | 15 (10 10) | 20 (62 -20) |
| | 15 (48.4%) | 20 (62.5%) |
| Reactive | 16 (51.6%) | 12 (37.5%) |
| Pulmonary compromise by tomography | 50.0 (40.0, 63.0) | 50.0 (42.0, 55.0) |

CP + SoC: Convalescent plasma plus standard of care; SoC: Standard of care alone.

291

292

293

294

295

296

297

Primary outcome and secondary mortality outcomes

The 28-day mortality was 25.8% (8 of 26 patients) in the convalescent plasma plus standard therapy group and 12.5% (4 of 12 patients) in the standard therapy alone group. At day 28, although mortality in the CP + SoC group was twice that of SoC, these differences were not statistically significant (RR = 2.06; 95% CI 0.73 to 7.11; p = 0.190).

Table 2. Clinical Results in patients who received CP + SoC compared with SoC only.

| Outcomes | Only SoC (n = 32) | CP + SoC (n = 31) | Risk Ratio or Hazard Ratio (95% CI); valor p |
|--|----------------------|----------------------|--|
| Primary outcome, death at 28 days; No. events (%) | 4 (12) | 8 (26) | Risk ratio; 2.06 (0.73 a 7.11); 0.190 |
| Secondary outcomes | | | |
| Death at 14 days; No. events (%) | 4 (12) | 7 (23) | Risk ratio; 2.06 (0.73 a 7.11); 0.190 |
| Time to ICU admission in 14 days; n events/person-time | 3 (384) | 6 (311) | Subhazard ratio; 2.21 (0.57 a 8.55); 0.250 |
| Time to ICU admission in 28 days; n events/person-time | 3 (720) | 6 (577) | Subhazard ratio; 2.21 (0.57 a 8.55); 0.250 |
| Time to invasive mechanical ventilation in 14 days; n events/person-time | 3 (382) | 6 (311) | Subhazard ratio; 2.30 (0.60 a 8.84); 0.230 |
| Time to invasive mechanical ventilation in 28 days; n events/person-time | 3 (718) | 6 (577) | Subhazard ratio; 2.19 (0.57 a 8.51); 0.260 |
| Time to death in 56 days; n events / person days | 4 (1473) | 8 (1339) | Hazard ratio; 2.56 (0.72 a 9.08); 0.147 |
| Adverse events; No. events (%) | | | |
| Any event | 6 (19) | 12 (39) | Odds ratio; 2.74 (0.90 a 9.10); 0.085 |
| Serious event | 2 (6.2) | 6 (19) | Odds ratio; 3.60 (0.75 a 26.1); 0.14 |
| Infusion related event | 0 | 0 | NA |

NA: Not apply

298

299

300

301

302

303

304

305

306

307

308

In the 56 days after enrollment, no statistically significant differences were found in the cumulative incidence curves of both groups (p = 0.196) (Fig 2). Similarly, there were no significant differences in the incidences of mortality (HR 2.21, 95% CI 0.66 to 7.33; p value = 0.182) (Table 2). The proportionality assumption of the Cox regression hazards was supported by the Grambsch and Therneau test (p = 0.450) and the Schoenfeld residual inspection.

Fig 2. Inverse Kaplan-Meier curves for cumulative incidence of death after treatment with CP + SoC versus SoC alone

Secondary efficacy outcomes No statistically significant differences were found in the cumulative incidence curves for admission to the ICU within 28 days (p = 0.251) (Fig 3A). The incidence rate of admission to the ICU within 28 days was 10.4 per 1000 patient days in the CP + SoC group and 4.17 per 1000 patient days in the group that received only SoC. Considering death as a competitive event, the Fine and Gray model revealed no statistically significant differences in the incidence of ICU admission between both groups (subHR 2.06; 95% CI 0.57 to 8.55; p = 0.250). Compared to standard treatment alone, the estimated effect of convalescent plasma + standard treatment was the same for ICU admission at 14 days (subHR 2.21; 95% CI 0.57 to 8.55; p = 0.250). No statistically significant differences were found in the cumulative incidence curves for admission to mechanical ventilation at 28 days (p = 0.256) (Fig 3B). The 28-day incidence rate of invasive mechanical ventilation was 10.4 per 1,000 patient days in the convalescent plasma plus standard therapy group and 4.18 per 1,000 patient days in the standard therapy only group. Compared to standard treatment alone, the estimated effect of convalescent plasma + standard treatment was the same for admission to mechanical

Fig 3. Cumulative incidence function curves for death (competing event) and (A) ICU admission or (B) mechanical ventilator admission after treatment with CP + SoC versus SoC alone

ventilation at 28 days (subHR 2.19; 95% CI 0.57 to 8.51; p = 0.260).

Safety results

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

No infusion-related adverse events were reported in study participants. Adverse events

were more common in the CP + SoC group (39%; 12 of 31 patients) than in the SoC group (19%; 6 of 32 patients). Similarly, serious adverse events were slightly more common in the CP + SoC group (19%; 6 of 31 patients) than in the SoC group (6.2%; 2 of 32 patients). However, there is high uncertainty regards the differences in the incidence of adverse events (OR 2.74; 95% CI, 0.90 to 9.10; p = 0.085) or serious adverse events (OR 3.60; 95% CI 0.75 to 26.1; p = 0.75) (Table 2 and S1 Table) if we consider the precision of these estimates and statistical significance.

Discussion

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

This study aimed to assess the efficacy and safety of convalescent plasma (CP) plus standard of care (SoC) versus SoC alone in adult patients hospitalized with COVID-19 but not yet requiring mechanical ventilation. Our results found no evidence that PC had an effect in reducing mortality at 28 days. We also found no evidence that the frequency of adverse events was higher in those who received PC than those who received SoC.

Our results agree with those widely reported in the literature. Although initially, systematic reviews with meta-analyses (24-26) found evidence of benefit in favor of PC to reduce mortality, these included observational studies (27–30) and clinical trials with significant limitations (18,31). More recent clinical trials reported no evidence of the benefit of PC in reducing mortality, admission to the ICU, or mechanical ventilation (17,32-45). Later meta-analyses also concluded no evidence of PC efficacy in reducing the incidence of these outcomes (8,24,25,38,46–52). Clinical practice guidelines recommend against using PC in hospitalized patients with COVID-19 with a strong level of recommendation and a high certainty of evidence (14,15,53).

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

The RECOVERY (34), CONCOR-1 (44), and REMAP-CAP (45) studies were the three largest clinical trials conducted to assess the efficacy and safety of convalescent plasma. and none found evidence of a benefit of high-dose CP in reducing mortality, ICU admission or mechanical ventilation in patients with COVID-19. Like our study, all of them were open-label and were stopped early. The RECOVERY trial (34) enrolled 11,558 patients (5,795 received CP + SoC and 5,763 received SoC). The study found evidence in favor of no significant differences (RR = 1.00; 95% CI 0.93-1.07) in 28-day mortality and other hospital outcomes such as mechanical ventilation. The CONCOR-1 trial (44), which enrolled 614 patients in the CP group and 307 in the SoC group, found no significant difference in its primary outcome of intubation or death at day 30 (RR = 1.16; 95%CI 0.94-1.43) nor in its secondary outcomes such as mortality, admission to intensive care and hospital stay. The REMAP-CAP trial (45), which enrolled 1084 critically ill patients in the PC group, and 916 in the control group, found no significant differences in in-hospital mortality outcomes. However, it did report potential for harm in patients who received convalescent plasma after the seven days of hospitalization. Regarding the safety of PC, to date, 51 clinical trials have been published that evaluated the use of PC, concluding, through a meta-analysis, that with a low degree of certainty, PC does not increase the occurrence of adverse events (15). Consistent with existing evidence, our study did not find any transfusion-related SAEs and, although there was a higher frequency of adverse events of any kind in the group treated with PC + SoC compared to the SoC group, these differences were not statistically significant. Observational surveillance studies suggest that adverse reactions are infrequent and related to conventional risks of plasma infusion for other indications. For example, a study

evaluating safety using records from 5,000 clinicians of hospitalized adult patients with severe COVID-19 found a low mortality rate of 0.3%. Likewise, the incidence of all serious adverse events (SAEs) in the first four hours after the transfusion was less than 1% (54). In addition to death (4 cases of 25 related SAEs), the main SAEs were transfusion-related circulatory overload (7 of 25 related SAEs), transfusion-related acute lung injury (11 of 25 SAEs), and severe transfusion-related allergic reactions (3 of 25 EAS). Months later, the update of this study extended the analysis to 20,000 patients, confirming the low frequency of adverse events: <1% for thrombotic and thromboembolic events and $\sim 3\%$ for cardiac events (55). This study has limitations to be considered. All patients had moderate to severe COVID-19, so our conclusions cannot be extrapolated to other groups of patients with different degrees of severity, especially patients with mild COVID-19. Another limitation is that the trial was open label, which could have influenced more subjective outcomes such as the recognition and/or reporting of some adverse events. However, these results are unlikely to have influenced hard outcomes such as mortality, ICU admission, or admission to mechanical ventilation. In conclusion, in our study, using CP + SoC in patients with moderate COVID-19 did not reduce mortality or improve other clinical outcomes at day 28 compared to SoC alone. Our results are consistent with the literature on the lack of benefit of CP and reinforce the evidence in favor of discouraging CP use in hospitalized patients with moderate to severe COVID-19.

References

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

- 1. Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, et al. 410
- COVID-19 Outbreak: An Overview. Chemotherapy. 2019;64(5–6):215–23. 411
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from 412 2.
- 413 Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-
- 33. 414
- 415 3. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
- epidemiology of 2019 novel coronavirus: implications for virus origins and 416
- 417 receptor binding. The Lancet. 2020 Feb 22;395(10224):565-74.
- Asili P, Mirahmad M, Tabatabaei-Malazy O, Manayi A, Haghighat E, Mahdavi M, 418
- et al. Characteristics of published/registered clinical trials on COVID-19 treatment: 419
- A systematic review. Daru J Fac Pharm Tehran Univ Med Sci. 2021 420
- 421 Dec;29(2):449-67.
- Marson P, Cozza A, De Silvestro G. The true historical origin of convalescent 422
- plasma therapy. Transfus Apher Sci. 2020 Oct;59(5):102847. 423
- Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, et al. 424
- 425 Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus.
- 2016 Mar; 14(2):152-7. 426
- Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, 427 7.
- 428 et al. Convalescent plasma in Covid-19: Possible mechanisms of action.
- Autoimmun Rev. 2020 Jul; 19(7): 102554. 429
- Vegivinti CTR, Pederson JM, Saravu K, Gupta N, Evanson KW, Kamrowski S, et 430
- al. Efficacy of convalescent plasma therapy for COVID-19: A systematic review 431
- and meta-analysis. J Clin Apheresis [Internet]. [cited 2021 May 14];n/a(n/a). 432
- Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jca.21881 433
- Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent 434
- 435 plasma or hyperimmune immunoglobulin for people with COVID-19: a living
- 436 systematic review. Cochrane Database Syst Rev [Internet]. 2020 Jul 10 [cited 2021
- Feb 8]:(7). Available from: 437
- https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub2/full 438
- Wang Y, Huo P, Dai R, Lv X, Yuan S, Zhang Y, et al. Convalescent plasma may 439
- 440 be a possible treatment for COVID-19: A systematic review. Int
- Immunopharmacol. 2021 Feb;91:107262. 441
- 11. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al. 442
- Association of Convalescent Plasma Treatment With Clinical Outcomes in 443
- 444 Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA. 2021
- Mar 23;325(12):1185–95. 445
- 12. Piscoya A, Ng-Sueng LF, Riego AP del, Cerna-Viacava R, Pasupuleti V, Thota P, 446
- et al. Efficacy and harms of convalescent plasma for treatment of hospitalized 447
- COVID-19 patients: a systematic review and meta-analysis. Arch Med Sci 448
- 449 [Internet]. 2021 Feb 18 [cited 2021 May 14]; Available from:

- https://www.archivesofmedicalscience.com/Efficacy-and-harms-of-convalescent-450
- plasma-for-treatment-of-hospitalized-COVID-19,132492,0,2.html 451
- 13. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al. 452
- 453 Convalescent plasma or hyperimmune immunoglobulin for people with
- 454 COVID-19: a living systematic review. Cochrane Database Syst Rev [Internet].
- 2021 [cited 2022 Apr 19];(5). Available from: 455
- 456 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub4/ap
- pendices 457
- 14. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID 458
- COVID-19 living guidelines: drug treatment and clinical management. Clin 459
- 460 Microbiol Infect. 2022 Feb;28(2):222-38.
- 461 Therapeutics and COVID-19: living guideline [Internet]. [cited 2022 Apr 19].
- Available from: https://www.who.int/publications-detail-redirect/WHO-2019-462
- nCoV-therapeutics-2022.2 463
- 464 16. Bajpai M, Maheshwari A, Dogra V, Kumar S, Gupta E, Kale P, et al. Efficacy of
- 465 convalescent plasma therapy in the patient with COVID-19: a randomised control
- trial (COPLA-II trial). BMJ Open. 2022 Apr 6;12(4):e055189. 466
- 17. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. 467
- Convalescent plasma in the management of moderate covid-19 in adults in India: 468
- open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 469
- 470 2020 Oct 22;371:m3939.
- 18. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early 471
- High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J 472
- Med. 2021 Feb 18;384(7):610-8. 473
- Hartmann J, Bloch EM, Burnouf T. Experience with COVID-19 convalescent 474
- plasma provides vital guidance to future pandemics. Transfusion (Paris). 475
- 2022;62(3):681-4. 476
- 20. Paneth N, Casadevall A, Pirofski L anne, Henderson JP, Grossman BJ, Shoham S, 477
- et al. WHO covid-19 drugs guideline: reconsider using convalescent plasma. BMJ. 478
- 479 2022 Feb 8;376:o295.
- Joyner MJ, Paneth NS, Senefeld JW, Fairweather D, Bruno KA, Wright RS, et al. 480
- Concerns about estimating relative risk of death associated with convalescent 481
- plasma for COVID-19. Nat Med. 2022 Jan;28(1):51-2. 482
- Schulz KF, Altman DG, Moher D, CONSORT 2010 Statement: updated guidelines 483
- 484 for reporting parallel group randomised trials. BMJ. 2010 Mar 24;340:c332.
- ENSAYOS CLINICOS INSTITUTO NACIONAL DE SALUD [Internet]. [cited 485
- 2022 May 41. Available from: 486
- https://www.ins.gob.pe/ensavosclinicos/rpec/recuperarECPBNuevoEN.asp?numec 487
- 488 =013-20


- Meher BR, Padhy BM, Das S, Mohanty RR, Agrawal K. Effectiveness of 489
- 490 Convalescent Plasma Therapy in the Treatment of Moderate to Severe COVID 19
- Patients: A Systematic Review and Meta-Analysis. J Assoc Physicians India. 2020 491
- 492 Dec;68(12):35-43.
- 25. Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of 493
- pharmacological interventions for the treatment of COVID-19: A systematic 494
- 495 review and network meta-analysis. PLOS Med. 2020 Dec 30;17(12):e1003501.
- 496 Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al.
- 497 The Effect of Convalescent Plasma Therapy on Mortality Among Patients With
- COVID-19: Systematic Review and Meta-analysis. Mayo Clin Proc. 2021 May 498
- 499 1;96(5):1262-75.
- 500 Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al.
- Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N 501
- Engl J Med. 2021 Mar 18;384(11):1015–27. 502
- 503 28. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al.
- 504 Convalescent plasma treatment of severe COVID-19: a propensity score-matched
- 505 control study. Nat Med. 2020 Nov;26(11):1708-13.
- Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. 506
- Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 507
- (COVID-19) Patients Transfused Early with Convalescent Plasma Containing 508
- 509 High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
- 2) Spike Protein IgG. Am J Pathol. 2021 Jan;191(1):90–107. 510
- 30. Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, et al. 511
- Early but not late convalescent plasma is associated with better survival in 512
- 513 moderate-to-severe COVID-19. PloS One. 2021;16(7):e0254453.
- O'Donnell MR, Grinsztein B, Cummings MJ, Justman JE, Lamb MR, Eckhardt 514
- CM, et al. A randomized double-blind controlled trial of convalescent plasma in 515
- adults with severe COVID-19. J Clin Invest. 2021 Jul 1;131(13):150646. 516
- 32. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent 517
- 518 Plasma Therapy on Time to Clinical Improvement in Patients With Severe and
- 519 Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020 Aug
- 520 4;324(5):460-70.
- Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez 521
- 522 C, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe
- 523 Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619–29.
- RECOVERY Collaborative Group. Convalescent plasma in patients admitted to 524
- 525 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label,
- 526 platform trial. Lancet Lond Engl. 2021 May 29;397(10289):2049-59.
- 35. Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, et al. 527
- 528 Results of the CAPSID randomized trial for high-dose convalescent plasma in
- 529 patients with severe COVID-19. J Clin Invest. 2021 Oct 15;131(20):e152264.

- 36. Avendaño-Solá C, Ramos-Martínez A, Muñez-Rubio E, Ruiz-Antorán B, Malo de 530
- 531 Molina R, Torres F, et al. A multicenter randomized open-label clinical trial for
- convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin 532
- Invest. 2021 Oct 15;131(20):e152740. 533
- 37. Baldeón ME, Maldonado A, Ochoa-Andrade M, Largo C, Pesantez M, Herdoiza 534
- M, et al. Effect of convalescent plasma as complementary treatment in patients 535
- 536 with moderate COVID-19 infection. Transfus Med Oxf Engl. 2022
- Apr;32(2):153-61. 537
- Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL, et al. 538
- Convalescent plasma for COVID-19 in hospitalised patients: an open-label, 539
- 540 randomised clinical trial. Eur Respir J. 2022 Feb;59(2):2101471.
- 541 van den Berg K, Glatt TN, Vermeulen M, Little F, Swanevelder R, Barrett C, et al.
- Convalescent plasma in the treatment of moderate to severe COVID-19 542
- pneumonia: a randomized controlled trial (PROTECT-Patient Trial). Sci Rep. 543
- 544 2022 Feb 15;12(1):2552.
- 545 40. AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab
- AH, et al. Randomized controlled trial of convalescent plasma therapy against 546
- standard therapy in patients with severe COVID-19 disease. Sci Rep. 2021 May 547
- 548 11;11:9927.
- Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, et 549
- al. The therapeutic potential of convalescent plasma therapy on treating critically-550
- ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, 551
- Iraq. Infez Med. 2020 Sep 1;28(3):357–66. 552
- Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. Efficacy 553 42
- and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A 554
- 555 Randomized Clinical Trial. JAMA Intern Med. 2022 Feb 1;182(2):115–26.
- 43. Holm K, Lundgren MN, Kjeldsen-Kragh J, Ljungquist O, Böttiger B, Wikén C, et 556
- al. Convalescence plasma treatment of COVID-19: results from a prematurely 557
- terminated randomized controlled open-label study in Southern Sweden. BMC Res 558
- 559 Notes. 2021 Dec 4;14(1):440.
- 44. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. 560
- 561 Convalescent plasma for hospitalized patients with COVID-19: an open-label,
- randomized controlled trial. Nat Med. 2021 Nov;27(11):2012–24. 562
- 563 Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF,
- McOuilten ZK, McVerry BJ, Al-Beidh F, et al. Effect of Convalescent Plasma on 564
- Organ Support-Free Days in Critically III Patients With COVID-19: A 565
- 566 Randomized Clinical Trial. JAMA. 2021 Nov 2;326(17):1690–702.
- 567 Snow TAC, Saleem N, Ambler G, Nastouli E, McCoy LE, Singer M, et al.
- Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and 568
- meta-regression. Br J Anaesth. 2021 Dec;127(6):834–44. 569

Kloypan C, Saesong M, Sangsuemoon J, Chantharit P, Mongkhon P. 570

571 CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and

- real-world evidence. Eur J Clin Invest. 2021 Nov;51(11):e13663. 572
- Peng HT, Rhind SG, Beckett A. Convalescent Plasma for the Prevention and 573
- 574 Treatment of COVID-19: A Systematic Review and Quantitative Analysis. JMIR
- Public Health Surveill. 2021 Apr 7;7(4):e25500. 575
- 49. Axfors C, Janiaud P, Schmitt AM, Van't Hooft J, Smith ER, Haber NA, et al. 576
- 577 Association between convalescent plasma treatment and mortality in COVID-19: a
- collaborative systematic review and meta-analysis of randomized clinical trials. 578
- BMC Infect Dis. 2021 Nov 20;21(1):1170. 579
- 580 50. Yang P, Wang J, Zheng R, Tan R, Li X, Liu X, et al. Convalescent plasma may not
- 581 be an effective treatment for severe and critically ill covid-19 patients: A
- Systematic Review & Meta-Analysis of Randomized Controlled Trials. Heart 582
- Lung J Crit Care. 2022 Jun;53:51-60. 583
- 584 Jorda A, Kussmann M, Kolenchery N, Siller-Matula JM, Zeitlinger M, Jilma B, et
- 585 al. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic
- Review and Meta-Analysis. Front Immunol. 2022;13:817829. 586
- Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, et al. Association of 587
- 588 Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With
- COVID-19: A Meta-analysis. JAMA Netw Open. 2022 Jan 4;5(1):e2147331. 589
- Convalescent Plasma and Immune Globulins [Internet]. COVID-19 Treatment 590
- Guidelines. [cited 2022 Apr 20]. Available from: 591
- https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-592
- antibody-products/convalescent-plasma/ 593
- Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. 594
- Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin 595
- Invest. 2020 Sep 1;130(9):4791-7. 596
- 55. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. 597
- 598 Safety Update. Mayo Clin Proc. 2020 Sep;95(9):1888–97.








Figure2




Figure3